HPVC2019-058: Pharmaceutical Products and IV Fluids
Current Contract
Contract start date: 30 Jan 2020
Contract end date: 29 Jan 2026
Option periods: Nil
Description
Contract for the provision of a range of pharmaceutical products and intravenous fluids to Victorian Public Health Services.Additional information
Update: 25 October 2024
HSV has made an update to Supplementary 025. Please find the updated information as below:
Upcoming Procurement Activity
Tentative Market Release Date: 30 October 2024
Tentative Market Closing Date: 15 November 2024
Title: HPVITS2019-058.025 Pharmaceutical Products and IV Fluids Supplementary 025
Scope:
SUBCATEGORY NUMBER |
SUBCATEGORY NAME |
43.01 |
ATOVAQUONE 750 MG/5 ML ORAL LIQUID, BOTTLE 210 ML |
310.04 |
METOCLOPRAMIDE 10 MG/2 ML INJECTION, AMPOULE/VIAL 2 ML, 10 |
324.06 |
MORPHINE SULFATE 10 MG/ML INJECTION, AMPOULE/VIAL 1 ML |
324.11 |
MORPHINE SULFATE 30 MG/ML INJECTION, AMPOULE/VIAL 1 ML |
324.12 |
MORPHINE SULFATE 5 MG/ML INJECTION, AMPOULE/VIAL 1 ML |
330.05 |
MYCOPHENOLATE 180 MG ENTERIC TABLET, 120 |
330.06 |
MYCOPHENOLATE 360 MG ENTERIC TABLET, 120 |
358.03 |
OXYCODONE HYDROCHLORIDE 10 MG/ML INJECTION, AMPOULE/VIAL 1 ML |
358.13 |
OXYCODONE HYDROCHLORIDE 20 MG/2 ML INJECTION, AMPOULE/VIAL 2 ML |
368.01 |
PARECOXIB 40 MG INJECTION, AMPOULE/VIAL |
390.02 |
POSACONAZOLE 40 MG/ML ORAL LIQUID, BOTTLE 105 ML |
424.02 |
RIVAROXABAN 10 MG TABLET 15 |
424.03 |
RIVAROXABAN 10 MG TABLET 30 |
424.04 |
RIVAROXABAN 15 MG TABLET 28 |
424.05 |
RIVAROXABAN 15 MG TABLET 42 |
424.06 |
RIVAROXABAN 20 MG TABLET 28 |
424.07 |
RIVAROXABAN 2.5 MG TABLET 60 |
426.01 |
ROCURONIUM BROMIDE 50 MG/5 ML INJECTION, AMPOULE/VIAL 5 ML |
443.01 |
SITAGLIPTIN 100 MG TABLET 28 |
443.02 |
SITAGLIPTIN 25 MG TABLET 28 |
443.03 |
SITAGLIPTIN 50 MG TABLET 28 |
456.06 |
TACROLIMUS 500 MICROGRAM MODIFIED RELEASE CAPSULE, 30 |
456.07 |
TACROLIMUS 1 MG MODIFIED RELEASE CAPSULE, 60 |
456.09 |
TACROLIMUS 3 MG MODIFIED RELEASE CAPSULE, 50 |
456.1 |
TACROLIMUS 5 MG MODIFIED RELEASE CAPSULE, 30 |
496.05 |
VALPROATE SODIUM 400 MG INJECTION, AMPOULE/VIAL |
532.01 |
DASATINIB 20 MG TABLET 60 |
532.02 |
DASATINIB 50 MG TABLET 60 |
532.03 |
DASATINIB 70 MG TABLET 60 |
532.04 |
DASATINIB 100 MG TABLET 30 |
541.01 |
ESMOLOL 100 MG INJECTION, AMPOULE/VIAL |
553.01 |
FOSAPREPITANT 150 MG INJECTION, AMPOULE/VIAL |
563.01 |
CICLOSPORIN 25 MG CAPSULE, 30 |
563.02 |
CICLOSPORIN 50 MG CAPSULE, 30 |
563.03 |
CICLOSPORIN 100 MG CAPSULE, 30 |
564.01 |
PENTAMIDINE 300 MG INJECTION, AMPOULE/VIAL |
565.01 |
MICAFUNGIN 50 MG INJECTION, AMPOULE/VIAL |
565.02 |
MICAFUNGIN 100 MG INJECTION, AMPOULE/VIAL |
83001.01 |
BEVACIZUMAB 100MG/4ML INJECTION, AMPOULE/VIAL, 4ML |
83001.02 |
BEVACIZUMAB 400MG/16ML INJECTION, AMPOULE/VIAL, 16ML |
All enquiries regarding this supplementary tender prior to the market release date should be directed to Daniel.Wakeling@healthsharevic.org.au or (03) 9947 3712.
Once the tender has been released, please direct all correspondence through the HSV Procurement Portal.
Important Note:
Please ensure that that you are registered to access the Procurement Portal and you’re your details are up to date. More information can be found on the HSV website,
or you can contact:
HSV Helpdesk
Phone: (03) 9947 3900
Email: helpdesk@healthsharevic.org.au
Tentative dates
Announcement of outcome to suppliers: 20 December 2024.
Announcement of outcome to health services: 20 December 2024.
Contract Commencement Date: 30 January 2025.
Categories
Category 1 - Pharmaceutical ProductsCategory 50,000 - Intravenous Fluids
Category 60,000 - Parenteral Nutrition Solutions
Category 70,000 - Irrigating Solutions
Category 80,000 - Biopharmaceuticals
Category 90,000 – Therapeutic Group Approach